Top 10 Biotechnology Startup Investors in Latvia in May 2026
Top 10 Biotechnology Startup Investors in Latvia in May 2026
| Investor | Biotechnology Latvia investments |
|---|---|
| Imprimatur Capital Fund Management | 6 |
| SOSV | 2 |
| Qiming Venture Partners USA | 2 |
| Abingworth | 2 |
| FlyCap | 2 |
| Alexandria Venture Investments | 1 |
| Roche Venture Fund | 1 |
| TSVC | 1 |
| Surveyor Capital | 1 |
| ZGI Capital | 1 |
Reach every investor
Get a list of investors who already back your industry, stage, and country. Emails & phones included.
Find investors — It's Free!Imprimatur Capital Fund Management is a venture capital firm focusing on high-technology at an early stage in its commercial development. We invest in start-up technology businesses which are based on innovative intellectual property, are led by strong teams and have high international growth potential.Imprimatur Capital Fund Management, based inLatvia, manages seed and start-up funds with investors including the Latvian Guarantee Agency, other institutional investors and some private investors. The company source investment opportunities primarily from the Baltic/Nordic/Russia region.Imprimatur Capital Fund Management is a partner firm of Imprimatur Capital Ltd, headquartered in London and with investment operations in Europe, Russia, Asia Pacific, Latin America and the US.
Show more...Investment focus
- Software, Information Technology, Apps
- Seed, Debt Financing, Funding Round
- Latvia, United States, United Kingdom
Portfolio highlights
- Axial3D — Leading the way with the latest 3D imaging, models, and devices
- afriQloud — AfriQloud provides a white-labeled cloud computing solution to telecom operators, internet service providers, system integrators, and managed information technology service providers.
- Sonarworks — SoundID Reference software calibrates your speakers and studio headphones, so you can trust that every mix will translate.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Qiming Venture Partners USA, founded in 2017, is a healthcare venture capital firm and healthcare investor with deep technical expertise that allows them to identify tomorrow's innovations early and strong operational experience with a hands-on approach that makes us the investor of choice for early-stage biotech companies.Because of theirproven, hands-on approach to supporting CEOs and scaling operations, its partners are frequently sought after to serve on company boards. They are respected business and thought leaders.
Show more...Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Series B, Post-IPO Equity
- United States, Canada, China
Portfolio highlights
- Icosavax — Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, whichit believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.
- Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
- Element Science — Now enrolling patients that are at high risk for sudden cardiac arrest.
We are Abingworth, a trans-atlantic bio-science investment firm with a deep understanding of both the science and markets we invest in.
Show more...Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, United Kingdom, France
Portfolio highlights
- Iambic — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
- CRISPR Therapeutics — CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from theirscientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
- Launch Therapeutics — Launch Therapeutics is a clinical development company that offers drug development, medical, clinical operations, and regulatory.
FlyCap AIF is a Venture Capital Fund of total size of 15.75 MEUR. The Fund provides growth capital for Latvia based SME’s in a form of investments in equity and mezzanine capital.
Show more...Investment focus
- Health Care, Rental, Medical
- Funding Round, Seed, Debt Financing
- Latvia, Estonia, The Netherlands
Portfolio highlights
- Tapcore — Tapcore is the only solution on the market that enables mobile developers to monetize pirated copies of their apps through advertising. Established in 2015, we are a remote company with headquarters in the Netherlands. Currently we serve over 150 million ad requests daily (and counting!).
- Purified — Purified is a nutritional supplement supplier.. It offers black chocolate produced by the best doctors in collaboration with scientists.
- Elmo — In our mobility-focused operations, we wanted to optimize business and decrease environmental impact, so we created remote control technology to deliver cars.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more...Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Canada, France
Portfolio highlights
- Tr1x — Tr1x develops cellular therapies intended for the treatment of autoimmune disorders.
- Proxima — Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches.
- NILO Therapeutics — A neuronal circuit regulates the immune system. We're targeting it to treat autoimmune and inflammatory diseases.
We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.
Show more...Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Spain
Portfolio highlights
- DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
- Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Founded in 2010, TSVC (formerly TEEC Angel Fund) is proud to be a leading early-stage venture capital fund in Silicon Valley.
Show more...Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Funding Round, Series A
- United States, China, Canada
Portfolio highlights
- Lumotive — Lumotive is a Seattle-based startup company developing high performance, solid-state lidar for autonomous systems in the automotive, UAV, robotics and related industries. The company's revolutionary beam-steering technology leverages Liquid Crystal Metasurfaces (or LCMs) implemented in mature semiconductor manufacturing processes to deliversmall, inexpensive 3D perception systems with unprecedented performance and reliability. For more information, visit us at www.lumotive.com.
- Petal Surgical — Petal is a surgical technology company pioneering incisionless surgery through Acoustic Sculpting, a proprietary form of boiling histotripsy. Our platform uses focused sound waves to precisely destroy harmful tissue without cuts, heat, or toxicity offering gentler alternative to traditional surgery.
- Carbon Free Energy Cloud — Carbon Credits Simplified
Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.
Show more...Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Post-IPO Equity, Series C
- United States, China, Switzerland
Portfolio highlights
- Adcytherix — Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer.
- Ventyx Biosciences — Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
- Triana Biomedicines — Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.
ZGI Capital is the fund management company that manages "ZGI fund”, that was founded to support entrepreneurs lacking start-up capital for their business. The total amount of assets available for venture capital investments is of EUR 7.4M. Combined with bank financing, this will allow to finance investment projects with total assets of up toEUR 30M. The fund acts on behalf of various investors including the State.
Show more...Investment focus
- Manufacturing, Machinery Manufacturing, Retail
- Funding Round, Seed, Debt Financing
- Latvia, Estonia
Portfolio highlights
- eAgronom — We enable companies to achieve their sustainability goals while supporting farmers in generating additional revenue, improving soil quality, and accessing better financing.
- KOOL Latvija — "KOOL Latvija" is a new concept gas station created in Latvia, which at the same time is also a convenient fast shopping place.
- Bioreactors.net — Biotechnical center is an innovative company and we provide solutions for industrial biotechnology processes, bioreactor manufacturing and industrial automation. We manufacture bioreactors for laboratory, pilot and industrial scale.
Contact investors today
Find who invests in your industry, stage, and country in 5 minutes.
Find investors — It's Free!